Form 4 for KPRX KIORA PHARMACEUTICALS INC
Accepted 2021-11-22 00:00:00 ET · period of report 2021-10-21 · accession 0001104659-21-142537 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-22 | 2021-10-21 | KPRX | Strem Brian M. | Pres, CEO, Dir | A - Grant | — | +9,517 | 9,517 | New | — | |
| 2021-11-22 | 2021-11-18 | KPRX | Strem Brian M. | Pres, CEO, Dir | P - Purchase | $1.41 | +17.9K | 27.4K | +188% | +$25.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-21 | A | A | 9,517 | — | 9,517 | D | — | — | (F1) Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021. |
| 2 | Common | Common Stock | 2021-11-18 | P | A | 17,853 | $1.41 | 27,370 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.41, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. |